title: Effects of neural stem cells and 5-fluorocytosine in canine metastatic lung tumor.
abstract: This is the first case report to describe the tumor regressive effect of systemic human neural stem cell (NSC)/5-fluorocytosine (5-FC) therapy on canine metastatic lung tumor. The therapeutic effects appeared approximately two weeks after 5-FC administration. Thoracic radiographs revealed a reduced number of lung nodules and decreased nodule size. However, there were no significant antitumor effects on primary lesions in abdominal organs. In conclusion, human NSC/5-FC prodrug therapy can secure patient quality of life with the same or more therapeutic effects and fewer side effects than other recommended chemotherapies.
authors: Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Korea.
authors: Yawon
authors: Y
authors: Hwang
authors: Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Korea.
authors: Dongwook
authors: D
authors: Kim
authors: Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Korea.
authors: Dongwoo
authors: D
authors: Chang
authors: Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Korea.
authors: Byeongwoo
authors: B
authors: Ahn
authors: Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Korea.|Division of Neurology, Department of Medicine, UBC Hospital, University of British Columbia, Vancouver, British Columbia V6T2B5, Canada.
authors: Yun-Bae
authors: YB
authors: Kim
authors: Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Korea.
authors: Gonhyung
authors: G
authors: Kim
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004283:Dog Diseases / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D004285:Dogs; D005437:Flucytosine / Q000008:administration & dosage / Q000627:therapeutic use*; D015316:Genetic Therapy / Q000379:methods / Q000662:veterinary; D006394:Hemangiosarcoma / Q000473:pathology / Q000628:therapy / Q000662:veterinary*; D008175:Lung Neoplasms / Q000473:pathology / Q000556:secondary / Q000628:therapy / Q000662:veterinary*; D008297:Male; D058953:Neural Stem Cells / Q000378:metabolism / Q000637:transplantation*; D011355:Prodrugs / Q000008:administration & dosage / Q000627:therapeutic use; D013902:Radiography, Thoracic / Q000662:veterinary; D013156:Splenectomy / Q000662:veterinary; D013160:Splenic Neoplasms / Q000556:secondary / Q000601:surgery / Q000662:veterinary; D033581:Stem Cell Transplantation / Q000379:methods / Q000662:veterinary*
chemical_list: D000970:Antineoplastic Agents; D011355:Prodrugs; D005437:Flucytosine
keywords: flucytosine; gene therapy; metastatic lung tumor; neural stem cells